Predictive Value of Interim Post-Therapy SPECT/ CTin Patients with Metastatic Castration-ResistantProstate Cancer Treated with [ 177 Lu] Lu-PSMA-617 (EANM 2026) - Sep 29, 2026 - Abstract #EP-0887; "Interim post-therapy SPECT/CT at cycle 4 provides clinically relevant prognostic information in mCRPC treated with [177Lu]Lu-PSMA-617. Adapted visual RECIP scoring derived from the RECIP 1.0 criteria is feasible and complementary to PSA, and combining both improves early risk stratification. The appearance of new lesions represents a strong adverse signal."
Clinical • Metastases • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor
|
|
L. Albe 1; P. Decazes 2; A. Dieudonne 2; F. Di Fiore 3; L. Augusto 3; S. Perret-Neveux 2; P. Bohn 1; P. Vera 1; D. Tonnelet 1; A. Edet-Sanson 1
|